Table 1.
Patient characteristics and treatment outcomes.
| Case | Age Sex | Interval between Initial Diagnosis and HSRT (Months) | Upfront RT Dose/fx | Upfront Chemotherapy (Cycles) | MGMT | IDH1 | 1p/19q |
|---|---|---|---|---|---|---|---|
| 1 | 60 Male | 12.6 | 60Gy/30 | TMZ (12) | + | - | - |
| 2 | 46 Female | 10.4 | 60Gy/30 | TMZ (6) | + | - | - |
| 3 | 55 Female | 14.8 | 60Gy/30 | TMZ (12) | + | - | + |
| 4 | 51 Male | 10.0 | 60Gy/30 | TMZ (4) | + | - | - |
| 5 | 43 Male | 7.0 | 60Gy/30 | TMZ (4) | + | - | - |
| Case | TERT | Recurrent Lesion | Recurrent PTV (cm3) | KPS at HSRS | Dose (iso-dose line) | Cycles of Anlotinib | F/U Interval from HSRS (months) |
| 1 | + | Left Frontal Lobe | 7.08 | 80 | 68 | 15 | 10 |
| 2 | + | Left Frontal Lobe | 26.94 | 80 | 65 | 14 | 10 |
| 3 | + | Left Occipital Lobe | 54.41 | 70 | 70 | 9 | 6 |
| 4 | + | Right Frontal Lobe | 5.53 | 90 | 70 | 4 | 4 |
| 5 | + | Left and Right Frontal Lobe | 44.33 | 90 | 68 | 8 | 6 |